The Atorvastatin Goal Achievement Across Risk Levels: (ATGOAL) study in Thailand.
Article
in English
| IMSEAR
| ID: sea-39430
ABSTRACT
OBJECTIVE:
To evaluate the efficacy and safety of atorvastatin at the starting doses of 10, 20, 40 mg and evaluate the effectiveness of 1 step titrate up regimen. MATERIAL ANDMETHOD:
Two hundred and forty two subjects with dyslipidemia were enrolled and assigned the appropriate dose in relation to their individual cardiovascular risk status and baseline LDL-C levels. If the NCEP targets were not achieved, the doses were titrated up at week 4 and the primary efficacy was evaluated at week 8.RESULTS:
A majority of subjects (88.8%) achieved their LDL-C goals at week 8. Almost all of the subject's LDL-C levels reached their goals by week 2 and 4 (81.6% and 87.1%, respectively). Only 10.7% (n = 25) required the sole titration. Each dose provided significant decreases in LDL-C (average -46.4%). Only 36 subjects experienced treatment related adverse events, the majority of these were in the high-risk group (n = 22) with only one subject registering a serious adverse event.CONCLUSION:
Atorvastatin is effective and safe for Thai patients with dyslipidemia. The appropriate starting dose has contributed in the achievement of cholesterol reduction.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Pyrroles
/
Aged, 80 and over
/
Aged
/
Female
/
Humans
/
Male
/
Adolescent
/
Treatment Outcome
/
Risk Assessment
/
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Type of study:
Etiology study
/
Risk factors
Limits:
Aged80
Language:
English
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS